Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Peyret

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Toxicology|June 12, 2012
Quantitative Property-Property Relationship for Screening-Level Prediction of Intrinsic Clearance of Volatile Organic Chemicals in Rats and Its Integration within PBPK Models to Predict Inhalation Pharmacokinetics in HumansThomas Peyret, Kannan Krishnan
Toxicology and Applied Pharmacology|September 28, 2010
A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicalsThomas Peyret, Patrick Poulin, Kannan Krishnan
Clinical and Translational Science|August 17, 2021
Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndromeJean-Francois Marier, Claudia Jomphe, Thomas Peyret, et al.
Virologie (Montrouge, France)|June 26, 2026
[ResaFlu/FluResearchNet International symposium,Toulouse, November 26-27, 2025]Charlotte Foret-Lucas, Margot Sarrat, Thomas Peyret, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 17, 2025
No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuriaLan Gao, Yongjun Hu, Neil Smith, et al.
Journal of Clinical Pharmacology|August 7, 2015
Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemiaXiaoping Zhang, Thomas Peyret, Nathalie H Gosselin, et al.
Clinical and Translational Science|May 3, 2024
Concentration-QTc modeling of sitravatinib in patients with advanced solid malignanciesAdam Dickinson, Yong Liu, Artem Uvarov, et al.
Cancer Chemotherapy and Pharmacology|June 23, 2016
Population pharmacokinetics of bevacizumab in cancer patients with external validationKelong Han, Thomas Peyret, Mathilde Marchand, et al.
Diagnostics (Basel, Switzerland)|June 24, 2022
The DendrisCHIP<sup>®</sup> Technology as a New, Rapid and Reliable Molecular Method for the Diagnosis of Osteoarticular InfectionsElodie Bernard, Thomas Peyret, Mathilde Plinet, et al.
Clinical Pharmacokinetics|September 6, 2024
Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's LymphomaMagali Chartier, Simone Filosto, Thomas Peyret, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Toxicology|June 12, 2012
Quantitative Property-Property Relationship for Screening-Level Prediction of Intrinsic Clearance of Volatile Organic Chemicals in Rats and Its Integration within PBPK Models to Predict Inhalation Pharmacokinetics in HumansThomas Peyret, Kannan Krishnan
Toxicology and Applied Pharmacology|September 28, 2010
A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicalsThomas Peyret, Patrick Poulin, Kannan Krishnan
Clinical and Translational Science|August 17, 2021
Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndromeJean-Francois Marier, Claudia Jomphe, Thomas Peyret, et al.
Virologie (Montrouge, France)|June 26, 2026
[ResaFlu/FluResearchNet International symposium,Toulouse, November 26-27, 2025]Charlotte Foret-Lucas, Margot Sarrat, Thomas Peyret, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 17, 2025
No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuriaLan Gao, Yongjun Hu, Neil Smith, et al.
Journal of Clinical Pharmacology|August 7, 2015
Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemiaXiaoping Zhang, Thomas Peyret, Nathalie H Gosselin, et al.
Clinical and Translational Science|May 3, 2024
Concentration-QTc modeling of sitravatinib in patients with advanced solid malignanciesAdam Dickinson, Yong Liu, Artem Uvarov, et al.
Cancer Chemotherapy and Pharmacology|June 23, 2016
Population pharmacokinetics of bevacizumab in cancer patients with external validationKelong Han, Thomas Peyret, Mathilde Marchand, et al.
Diagnostics (Basel, Switzerland)|June 24, 2022
The DendrisCHIP<sup>®</sup> Technology as a New, Rapid and Reliable Molecular Method for the Diagnosis of Osteoarticular InfectionsElodie Bernard, Thomas Peyret, Mathilde Plinet, et al.
Clinical Pharmacokinetics|September 6, 2024
Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's LymphomaMagali Chartier, Simone Filosto, Thomas Peyret, et al.
Pageof 2